Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization

References

• Klein RM, Green S. The development of lacquer cracks in pathologic myopia. American Journal of Ophthalmology. 1988;106(3):282–285.
   PubMed Web of Science ®Google Scholar
• Ohno-Matsui K, Wu PC, Yamashiro K, et al. IMI pathologic myopia. Invest Ophthalmol Vis Sci. 2021 Apr 28;62:5.
   PubMed Web of Science ®Google Scholar
• Ohno-Matsui K, Kawasaki R, Jonas JB, et al. International photographic classification and grading system for myopic maculopathy. Am J Ophthalmol. 2015;159:877–883.
   PubMed Web of Science ®Google Scholar
• Moriyama M, Ohno-Matsui K, Hayashi K, et al. Topographic analyses of shape of eyes with pathologic myopia by high-resolution three-dimensional magnetic resonance imaging. Ophthalmology 2011;118:1626–1637.
   PubMed Web of Science ®Google Scholar
• Wong TY, Ferreira A, Hughes R, et al. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol. 2014;157:9–25.
   PubMed Web of Science ®Google Scholar
• Wong TY, Ohno-Matsui K, Leveziel N, et al. Myopic choroidal neovascularisation: current concepts and update on clinical management. Br J Ophthalmol. 2015;99:289–296.
   PubMed Web of Science ®Google Scholar
• Cohen SY, Laroche A, Leguen Y, et al. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996;103:1241–1244.
   PubMed Web of Science ®Google Scholar
• Secretan M, Kuhn D, Soubrane G, et al. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol. 1997;7:307–316.
   PubMedGoogle Scholar
• Tabandeh H, Flynn HW Jr., Scott IU, et al. Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 1999;106:2063–2067.
   PubMed Web of Science ®Google Scholar
• Bottoni F, Tilanus M. The natural history of juxtafoveal and subfoveal choroidal neovascularization in high myopia. International Ophthalmology. 2001;24(5):249–255.
   PubMedGoogle Scholar
• Yoshida T, Ohno-Matsui K, Ohtake Y, et al. Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups. Ophthalmology 2002;109(4):712–719.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Ohno-Matsui K, Yoshida T, et al. Characteristics of patients with a favorable natural course of myopic choroidal neovascularization. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2005;243(1):13–19.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003;110(7):1297–1305.
   PubMed Web of Science ®Google Scholar
• Neelam K, Cheung CM, Ohno-Matsui K, et al. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res. 2012;31:495–525.
   PubMed Web of Science ®Google Scholar
• Lai TY, Cheung CM. Myopic choroidal neovascularization: diagnosis and treatment. Retina 2016;36:1614–1621.
   PubMed Web of Science ®Google Scholar
• Chan WM, Lai TY, Chan KP, et al. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina 2008;28:1308–1313.
   PubMed Web of Science ®Google Scholar
• Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors. PLoS One. 2008;3(11):e3554.
   PubMed Web of Science ®Google Scholar
• Lai TYY, Staurenghi G, Lanzetta P, et al. Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina 2018;38:1464–1477.
   PubMed Web of Science ®Google Scholar
• Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthalmol. 2008;53:121–138.
   PubMed Web of Science ®Google Scholar
• Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no 3. Ophthalmology. 2003;110:667–673.
   PubMed Web of Science ®Google Scholar
• Giansanti F, Virgili G, Donati MC, et al. Long-term results of photodynamic therapy for subfoveal choroidal neovascularization with pathologic myopia. Retina 2012;32:1547–1552.
   PubMed Web of Science ®Google Scholar
• Ng DSC, Fung NSK, Yip FLT, et al. Ranibizumab for myopic choroidal neovascularization. Expert Opin Biol Ther. 2020;20:1385–1393.
   PubMed Web of Science ®Google Scholar
• Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 2014;121:682–692.
   PubMed Web of Science ®Google Scholar
• Holz FG, Tufail A, Leveziel N, et al. Ranibizumab in myopic choroidal neovascularization: a subgroup analysis by ethnicity, age, and ocular characteristics in RADIANCE. Ophthalmologica 2016;236:19–28.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859–870.
   PubMed Web of Science ®Google Scholar
• Rodrigues EB, Farah ME, Maia M, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res. 2009;28:117–144.
   PubMed Web of Science ®Google Scholar
• Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27:536–544.
   PubMed Web of Science ®Google Scholar
• Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetes and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina 2017;37:1847–1858.
   PubMed Web of Science ®Google Scholar
• Xu L, Lu T, Tuomi L, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci. 2013;54:1616–1624.
   PubMed Web of Science ®Google Scholar
• Tufail A, Patel PJ, Sivaprasad S, et al. Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye (Lond). 2013;27:709–715.
   PubMed Web of Science ®Google Scholar
• Tufail A, Narendran N, Patel PJ, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology 2013;120:1944–1945.
   PubMed Web of Science ®Google Scholar
• Chen Y, Sharma T, Li X, et al. Ranibizumab versus verteporfin photodynamic therapy in Asian patients with myopic choroidal neovascularization: BRILLIANCE, a 12-month, randomized, double-masked study. Retina. 2019;39:1985–1994.
   PubMed Web of Science ®Google Scholar
• Hamilton RD, Clemens A, Minnella AM, et al. Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: results from the LUMINOUS study. PLoS One. 2020;15(1):e0227557.
   PubMed Web of Science ®Google Scholar
• Wu TT, Kung YH. Five-year outcomes of intravitreal injection of ranibizumab for the treatment of myopic choroidal neovascularization. Retina 2017;37:2056–2061.
   PubMed Web of Science ®Google Scholar
• Onishi Y, Yokoi T, Kasahara K, et al. Five-year outcomes of intravitreal ranibizumab for choroidal neovascularization in patients with pathologic myopia. Retina 2019;39:1289–1298.
   PubMed Web of Science ®Google Scholar
• Kang EC, Seo JG, Kim BR, et al. Clinical outcomes of intravitreal bevacizumab versus photodynamic therapy with or without bevacizumab for myopic choroidal neovascularization: a 7-year follow-up study. Retina 2017;37:1775–1783.
   PubMed Web of Science ®Google Scholar
• Parravano M, Scarinci F, Gilardi M, et al. Patchy chorioretinal atrophy changes at the posterior pole after ranibizumab for myopic choroidal neovascularization. Invest Ophthalmol Vis Sci. 2017;58:6358–6364.
   PubMed Web of Science ®Google Scholar
• Lai TY, Luk FO, Lee GK, et al. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond). 2012;26:1004–1011.
   PubMed Web of Science ®Google Scholar
• Huang J, Chen T, Lu Y, et al. Retinoschisis and intravitreal ranibizumab treatment for myopic choroidal neovascularization. Chin Med J (Engl). 2014;127:2053–2057.
   PubMed Web of Science ®Google Scholar
• Ceklic L, Munk MR, Wolf-Schnurrbusch U, et al. Visual acuity outcomes of ranibizumab treatment in pathologic myopic eyes with macular retinoschisis and choroidal neovascularization. Retina 2017;37:687–693.
   PubMed Web of Science ®Google Scholar
• Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171–185.
   PubMed Web of Science ®Google Scholar
• Balaratnasingam C, Dhrami-Gavazi E, McCann JT, et al. Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration. Clin Ophthalmol. 2015;9:2355–2371.
   PubMed Web of Science ®Google Scholar
• Ikuno Y, Ohno-Matsui K, Wong TY, et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. Ophthalmology. 2015;122(6):1220–1227.
   PubMed Web of Science ®Google Scholar
• Sayanagi K, Uematsu S, Hara C, et al. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2019;257:749–757.
   PubMed Web of Science ®Google Scholar
• Korol AR, Zadorozhnyy OS, Naumenko VO, et al. Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study. Clin Ophthalmol (Auckland, NZ). 2016;10:2223–2229.
   PubMed Web of Science ®Google Scholar
• Pece A, Milani P. Intravitreal aflibercept for myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2016;254:2327–2332.
   PubMedGoogle Scholar
• Bruè C, Pazzaglia A, Mariotti C, et al. Aflibercept as primary treatment for myopic choroidal neovascularisation: a retrospective study. Eye (Lond). 2016;30:139–145.
   PubMed Web of Science ®Google Scholar
• Corazza P, Kabbani J, Soomro T, et al. Three-year real-world outcomes of intravitreal anti-VEGF therapies in patients affected by myopic choroidal neovascularization. Eur J Ophthalmol. 2020;1120672120963455.
   Web of Science ®Google Scholar
• Zhang Y, Han Q, Ru Y, et al. Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application. Drug Des Devel Ther. 2015;9:3413–3421.
   PubMed Web of Science ®Google Scholar
• Lu X, Sun X. Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des Devel Ther. 2015;9:2311–2320.
   PubMed Web of Science ®Google Scholar
• Chen Y Efficacy and safety of conbercept ophthalmic injection in treatment of choroidal neovascularization secondary to pathological myopia (Shiny trial). Presented in angiogenesis, exudation and degeneration meeting 2016, Miami, FL.
   Google Scholar
• Lumitin (conbercept) ophthalmic injection drug insert. cited 2021 Mar 31. Available from http://yao.dxy.com/drug/148462.htm
   Google Scholar
• Zhou Y, Yang S, Yuan Y, et al. Progression and new onset of macular retinoschisis in myopic choroidal neovascularization eyes after conbercept therapy: a post-hoc analysis. Eye (Lond). 2020;34:523–539.
   PubMed Web of Science ®Google Scholar
• Sun CB, Wang Y, Zhou S, et al. Macular hole retinal detachment after intravitreal Conbercept injection for the treatment of choroidal neovascularization secondary to degenerative myopia: a case report. BMC Ophthalmol. 2019;19:156.
   PubMed Web of Science ®Google Scholar
• Cheng LN, Lin YX, Liu L, et al. Assessment of conbercept therapy for high myopia macular neovascularization by optical coherence tomography angiography. Sci Rep. 2020;10:16959.
   PubMed Web of Science ®Google Scholar
• Yan M, Huang Z, Lian HY, et al. Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia. Acta Ophthalmol. 2019;97:e813–e4.
   PubMed Web of Science ®Google Scholar
• Nie X, Wang Y, Yi H, et al. Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real-world setting in China: intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization. BMC Ophthalmol. 2021;21:116.
   PubMed Web of Science ®Google Scholar
• Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol. 2006;142:660–668.
   PubMed Web of Science ®Google Scholar
• Amit L, Ben-Aharon I, Vidal L, et al. The impact of bevacizumab (avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review. PLoS One. 2013;8:e51780.
   PubMed Web of Science ®Google Scholar
• Peiretti E, Vinci M, Fossarello M. Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results. Can J Ophthalmol. 2012;47:28–33.
   PubMed Web of Science ®Google Scholar
• Iacono P, Parodi MB, Papayannis A, et al. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina 2012;32:1539–1546.
   PubMed Web of Science ®Google Scholar
• Gharbiya M, Cruciani F, Parisi F, et al. Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia. Br J Ophthalmol. 2012;96:1068–1072.
   PubMed Web of Science ®Google Scholar
• Ikuno Y, Nagai Y, Matsuda S, et al. Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol. 2010;149:140–146.
   PubMed Web of Science ®Google Scholar
• Baba T, Kubota-Taniai M, Kitahashi M, et al. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol. 2010;94:864–870.
   PubMed Web of Science ®Google Scholar
• Macky TA, Mahgoub MM. Electrophysiological assessment of optic nerve and retinal functions following intravitreal injection of bevacizumab (avastin). J Ocul Pharmacol Ther. 2012;28:159–165.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Ohno-Matsui K, Shimada N, et al. Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology 2010;117:1595–1611.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Shimada N, Moriyama M, et al. Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia. Retina 2012;32:687–695.
   PubMed Web of Science ®Google Scholar
• Oishi A, Yamashiro K, Tsujikawa A, et al. Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2013;251:1–7.
   PubMed Web of Science ®Google Scholar
• Shimada N, Ohno-Matsui K, Hayashi K, et al. Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularization. Jpn J Ophthalmol. 2011;55:378–382.
   PubMed Web of Science ®Google Scholar
• Kasahara K, Moriyama M, Morohoshi K, et al. Six-year outcomes of intravitreal bevacizumab for choroidal neovascularization in patients with pathologic myopia. Retina 2017;37:1055–1064.
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno JM, Arias L, Montero JA, et al. Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome. Br J Ophthalmol. 2013;97:1447–1450.
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno JM, Montero JA, Araiz J, et al. Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to pathologic myopia: six years outcome. Retina 2015;35:2450–2456.
   PubMed Web of Science ®Google Scholar
• Sarao V, Veritti D, Macor S, et al. Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes. Graefes Arch Clin Exp Ophthalmol. 2016;254:445–454.
   PubMed Web of Science ®Google Scholar
• Freitas-da-Costa P, Pinheiro-Costa J, Carvalho B, et al. Anti-VEGF therapy in myopic choroidal neovascularization: long-term results. Ophthalmologica. 2014;232(1):57–63.
   PubMed Web of Science ®Google Scholar
• Patel A, Sun W. Ziv-aflibercept in metastatic colorectal cancer. Biologics 2014;8:13–25.
   PubMedGoogle Scholar
• Lai TYY, Cheung CMG, Mieler WF. Ophthalmic application of anti-VEGF therapy. Asia Pac J Ophthalmol (Phila). 2017;6:479–480.
   PubMed Web of Science ®Google Scholar
• Singh SR, Dogra A, Stewart M, et al. Intravitreal ziv-aflibercept: clinical effects and economic impact. Asia Pac J Ophthalmol (Phila). 2017;6:561–568.
   PubMed Web of Science ®Google Scholar
• Malik D, Tarek M, Caceres del Carpio J, et al. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol. 2014;98(Suppl 1):11.
   PubMed Web of Science ®Google Scholar
• Chhablani J, Narayanan R, Mathai A, et al. Short-term safety profile of intravitreal ziv-aflibercept. Retina 2016;36:1126–1131.
   PubMed Web of Science ®Google Scholar
• Braimah IZ, Stewart M, Videkar C, et al. Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration. Br J Ophthalmol. 2017;101:1201–1205.
   PubMed Web of Science ®Google Scholar
• Chhablani J, Dedhia CJ, Peguda HK, et al. Short-term safety of 2 mg intravitreal ziv-aflibercept. Retina 2017;37:1859–1865.
   PubMed Web of Science ®Google Scholar
• Nawar AE, Shafik HM. Pilot study of ziv-aflibercept in myopic choroidal neovascularisation patients. BMC Ophthalmol. 2020;20:414.
   PubMed Web of Science ®Google Scholar
• Singh SR, Stewart MW, Chattannavar G, et al. Safety of 5914 intravitreal ziv-aflibercept injections. Br J Ophthalmol. 2019;103:805–810.
   PubMed Web of Science ®Google Scholar
• Lai TY. Anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization: do we need more evidence? Retina 2012;32:1443–1445.
   PubMed Web of Science ®Google Scholar
• Cheung CMG, Arnold JJ, Holz FG, et al. Myopic choroidal neovascularization: review, guidance, and consensus statement on management. Ophthalmology 2017;124:1690–1711.
   PubMed Web of Science ®Google Scholar
• Willis J, Morse L, Vitale S, et al. Treatment patterns for myopic choroidal neovascularization in the United States: analysis of the IRIS registry. Ophthalmology 2017;124:935–943.
   PubMed Web of Science ®Google Scholar
• Ikuno Y. Overview of the complications of high myopia. Retina 2017;37:2347–2351.
   PubMed Web of Science ®Google Scholar
• Baek SU, Park IW, Suh W. Long-term intraocular pressure changes after intravitreal injection of bevacizumab. Cutan Ocul Toxicol. 2016;35:310–314.
   PubMed Web of Science ®Google Scholar
• Eadie BD, Etminan M, Carleton BC, et al. Association of repeated intravitreous bevacizumab injections with risk for glaucoma surgery. JAMA Ophthalmol. 2017;135:363–368.
   PubMed Web of Science ®Google Scholar
• Gómez-Mariscal M, Puerto B, Muñoz-Negrete FJ, et al. Acute and chronic optic nerve head biomechanics and intraocular pressure changes in patients receiving multiple intravitreal injections of anti-VEGF. Graefes Arch Clin Exp Ophthalmol. 2019;257:2221–2231.
   PubMed Web of Science ®Google Scholar
• Mayr-Sponer U, Waldstein SM, Kundi M, et al. Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration. Ophthalmology 2013;120:2620–2629.
   PubMed Web of Science ®Google Scholar
• Munk MR, Arendt P, Yu S, et al. The impact of the vitreomacular interface in neovascular age-related macular degeneration in a treat-and-extend regimen with exit strategy. Ophthalmol Retina. 2018;2:288–294.
   PubMedGoogle Scholar
• Risk factors for idiopathic rhegmatogenous retinal detachment. The eye disease case-control study group. Am J Epidemiol. 1993. 137: 749–757.
   PubMed Web of Science ®Google Scholar
• Sultan ZN, Agorogiannis EI, Iannetta D, et al. Rhegmatogenous retinal detachment: a review of current practice in diagnosis and management. BMJ Open Ophthalmol. 2020;5:e000474.
   PubMed Web of Science ®Google Scholar
• Storey PP, Pancholy M, Wibbelsman TD, et al. Rhegmatogenous retinal detachment after intravitreal injection of anti-vascular endothelial growth factor. Ophthalmology 2019;126:1424–1431.
   PubMed Web of Science ®Google Scholar
• Wei Q, Jiang C, Ye X, et al. Vitreous proteomics provides new insights into antivascular endothelial growth factor therapy for pathologic myopia choroid neovascularization. J Interferon Cytokine Res. 2019;39:786–796.
   PubMed Web of Science ®Google Scholar
• Ohno-Matsui K, Lai TY, Lai CC, et al. Updates of pathologic myopia. Prog Retin Eye Res. 2016;52:156–187.
   PubMed Web of Science ®Google Scholar
• Ohno-Matsui K, Jonas JB, Spaide RF. Macular bruch membrane holes in choroidal neovascularization-related myopic macular atrophy by swept-source optical coherence tomography. Am J Ophthalmol. 2016;162(133–139):e1.
   PubMedGoogle Scholar
• Lee JH, Lee SC, Kim SH, et al. Choroidal thickness and chorioretinal atrophy in myopic choroidal neovascularization with anti-vascular endothelial growth factor therapy. Retina 2017;37:1516–1522.
   PubMed Web of Science ®Google Scholar
• Hussain RM, Weng CY, Wykoff CC, et al. Abicipar pegol for neovascular age-related macular degeneration. Expert Opin Biol Ther. 2020 Sep;20(9):999–1008. Epub 2020 Jul 3. PMID: 32552072.
   PubMed Web of Science ®Google Scholar
• Anderson WJ, Da Cruz NFS, Lima LH, et al. Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. International Journal of Retina and Vitreous. 2021 May;7(1):37.
   PubMedGoogle Scholar
• Khurana RN, Kunimoto D, Yoon YH, et al. Two-year results of the phase 3 randomized controlled study of abicipar in neovascular age-related macular degeneration. Ophthalmology. 2020 Nov;19:S0161-6420(20)31109-X.
   Google Scholar
• Monés J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2020 Nov;15:S0161-6420(20)31075–7.
   Google Scholar
• Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program. Media release on 28 May 2021. cited 2021 Jun 6. Available from https://www.novartis.com/news/media-releases/novartis-reports-one-year-results-phase-iii-merlin-study-evaluating-beovu-every-four-week-dosing-and-provides-update-beovu-clinical-program
   Google Scholar
• Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. British Journal of Ophthalmology. 2014;98(12):1636–1641.
   PubMed Web of Science ®Google Scholar
• Jin E, Bai Y, Luo L, et al. Serum levels of vascular endothelial growth factor before and after intravitreal injection of ranibizumab or conbercept for neovascular age-related macular degeneration. Retina 2017;37(5):971–977.
   PubMed Web of Science ®Google Scholar
• Wu Z, Huang J, Sadda S. Inadvertent use of bevacizumab to treat choroidal neovascularisation during pregnancy: a case report. Ann Acad Med Singap. 2010;39:143–145.
   PubMed Web of Science ®Google Scholar
• Introini U, Casalino G, Cardani A, et al. Intravitreal bevacizumab for a subfoveal myopic choroidal neovascularization in the first trimester of pregnancy. Journal of Ocular Pharmacology and Therapeutics. 2012;28(5):553–555.
   PubMed Web of Science ®Google Scholar
• Polizzi S, Mahajan VB. Intravitreal anti-VEGF injections in pregnancy: case series and review of literature. Journal of Ocular Pharmacology and Therapeutics. 2015;31(10):605–610.
   PubMed Web of Science ®Google Scholar